Eleanor directs editorial content produced by the Commercial Pharma Insights team (Scrip, Generics Bulletin and In Vivo) in the US and Europe, liaising closely with counterparts in policy and regulatory coverage and in Asia. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders. Eleanor joined Citeline predecessor Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Citeline's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. She regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.
Latest from Eleanor Malone
Industry leaders predict pricing uncertainty will force companies to abandon blanket global launches. However, AI platforms will reshape commercial execution and new access models will break down barriers limiting patient reach.
Scrip Asks... What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped
Industry leaders predict that competitive dynamics in 2026 will be fundamentally reshaped by China's speed and cost advantages, forcing western biopharma to rethink what it takes to win. Meanwhile, the sustainability of traditional biotech's role as innovation middleman is called into question.
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.
Merck & Co.’s checkpoint inhibitor Keytruda remains the best-selling drug worldwide. The top 10 products generated nearly $47bn in third-quarter revenues for big pharma, boosted by swelling sales of obesity drugs.
Eli Lilly’s Mounjaro overtook rival GLP-1 agonist Ozempic from Novo Nordisk to become the second-highest selling drug globally in the second quarter of 2025, while overall GLP-1 drug sales continued to swell.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.